Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Parkinson’s, Autoimmune Disorders May Share Genetic Common Ground

Joan Stephenson  |  

NEW YORK (Reuters Health)—Parkinson’s disease and some autoimmune diseases may have genetic risk factors in common, raising the possibility that the immune system may influence Parkinson’s disease pathogenesis, new research suggests. The study, which analyzed data from genome-wide association studies, “showed a considerable genetic overlap between [Parkinson’s disease] and autoimmune diseases, in particular, type 1…

Tight RA Control Via Telemedicine Noninferior to Conventional Clinic Visits

Reuters Staff  |  

NEW YORK (Reuters Health—Telemedicine follow up based on patient-reported outcome (PRO) is noninferior to conventional outpatient care for tight control of disease activity in rheumatoid arthritis (RA) patients with low disease activity or remission, new findings show. “Even though patients in the [telemedicine] follow-up groups requested more acute visits, they over-all had a more than…

Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome

  |  

The P2X7 receptor inflammasome axis may have a role in the pathogenesis of Sjögren’s syndrome and non-Hodgkin’s lymphoma. According to new research, patients with Sjögren’s syndrome who developed non-Hodgkin’s lymphoma had an increased expression of the P2X7R-inflammasome axis and the glandular expression of IL-18, suggesting a possible novel biomarker…

FDA Asks Endo to Withdraw Opana ER Opioid

Reuters Staff  |  

(Reuters)—The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company’s shares down as much as 13%. “After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer…

IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk

Reuters Staff  |  

NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…

Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?

Marilynn Larkin  |  

(Reuters Health)—A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn’t have dangerous side effects, researchers say. Dr. Jean-Yves Reginster of Liege State University in Belgium and colleagues recruited 604 people over age 50 with knee osteoarthritis (OA) from five European countries and randomly assigned…

Anthem Plans to Leave Obamacare Insurance Market in Ohio in 2018

Reuters Staff  |  

(Reuters)—Anthem Inc., one of the largest sellers of Obamacare individual health insurance, will exit most of the Ohio market next year because of volatility and uncertainty about whether the government will continue to provide subsidies aimed at making the plans affordable, it said on Tuesday. Republicans are trying to cut off the subsidy payments in…

AbbVie’s Rheumatoid Arthritis Drug Succeeds in Late-Stage Trial

Reuters Staff  |  

(Reuters)—U.S. drugmaker AbbVie Inc said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to standard treatments. Two doses of the drug, upadacitinib, induced a statistically significant reduction in symptoms compared to a placebo in the 12-week long study,…